[Therapy of primary brain tumors with segidrin]

The results of segidrin administration to 46 patients with malignant and 6 patients with benign tumors of the brain are presented. Pronounced therapeutic effect for the whole group was 63.5% and 73%, if partial regression of neurologic symptoms in the entire brain and separate foci is considered. These indexes for patients with malignant tumors only were 61 and 71.7%, respectively. Since segidrin has virtually no significant untoward side-effects, it is considered a most safe medicine for managing brain tumors. It is recommended in cases of inoperable tumor and for post-operative adjuvant chemotherapy with a view to extending the patient's survival time and improving the quality of life.